Home/Healthcare/Diagnostics/Liquid Biopsy for Treatment Monitoring (MRD) Market

Liquid Biopsy for Treatment Monitoring (MRD) Market - Strategic Insights and Forecasts (2026-2031)

Market Size, Share, Forecasts and Trends Analysis By Technology (NGS-Based Liquid Biopsy, PCR-Based Liquid Biopsy, Digital PCR, Multiplex Assays, Multi-Omics Platforms), By Biomarker Type (ctDNA, cfDNA, Circulating Tumor Cells, RNA Biomarkers, Epigenetic Biomarkers), By Cancer Type (Hematologic Malignancies, Solid Tumors), By Application (Treatment Response Monitoring, Recurrence Monitoring, Therapy Selection, Prognostic Assessment), By End User (Hospitals, Cancer Specialty Centers, Reference Laboratories, Academic & Research Institutes), By Sample Type (Blood, Plasma, Bone Marrow, Other Biofluids), By Distribution Channel (Direct Sales, Reference Laboratory Services, Hospital Procurement Networks), and Geography

$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

Liquid Biopsy for Treatment Monitoring (MRD) Market Report

Report IDKSI-008685
PublishedMay 2026
Pages153
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

Growth is being driven by increasing demand for early relapse detection, rising adoption of personalized oncology monitoring, integration of MRD endpoints into clinical trials, and expansion of high-sensitivity sequencing technologies.

Key technologies include next-generation sequencing (NGS), digital PCR, multiplex assays, and emerging multi-omics platforms integrating genomic, RNA, and epigenetic data.

Applications include treatment response monitoring, recurrence prediction, longitudinal cancer surveillance, therapy selection, and post-surgical relapse detection.

Challenges include high assay complexity, reimbursement variability, lack of standardized ctDNA thresholds, and the need for advanced sequencing infrastructure and bioinformatics capabilities.

North America benefits from advanced oncology infrastructure, strong reimbursement support, widespread NGS adoption, and growing use of ctDNA monitoring in cancer care pathways.

Need data specifically for your business?Request Custom Research →
Related Reports

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon